300009.SHE Anhui Anke BioTech Group
- Market cap
- CNY 13.1B
- P/E
- 19.7x
- P/B
- 2.96x
- ROE
- 14.2%
- Dividend yield
- 3.15%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 300009.SHE undervalued?
Graham number300009.SHE trades 60.8% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Anhui Anke BioTech Group fundamental analysis
No fundamental analysis for Anhui Anke BioTech Group yet.
Anhui Anke BioTech Group stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Anhui Anke BioTech Group
Anhui Anke Biotechnology (Group) Co., Ltd. engages in the biopharmaceutical industry in China and internationally. It offers human growth hormone for injection under the Ansomone name; and recombinant human interferon alpha 2b lyophilized powder, liquid, and prefilled syringe for injection, as well as recombinant human interferon alpha 2b cream, eye drop, and suppository under the Anterferon name. The company provides anti-sperm antibody, semen leukocyte peroxidase staining,…
Full company profileAnhui Anke BioTech Group financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Anhui Anke BioTech Group annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 849M | 1.10B | 1.46B | 1.71B | 1.70B | 2.17B | 2.33B | 2.87B | 2.54B | 2.65B | 2.20B |
| Gross Profit | 628M | 851M | 1.17B | 1.33B | 1.34B | 1.73B | 1.82B | 2.24B | 1.95B | 2.00B | 1.66B |
| Operating Income | 219M | 329M | 311M | 165M | 424M | 297M | 842M | 924M | 806M | 841M | 725M |
| EBITDA | 262M | 355M | 395M | 462M | 463M | 677M | 836M | 993M | 846M | 959M | 737M |
| Net Income | 197M | 278M | 263M | 124M | 359M | 207M | 703M | 847M | 707M | 735M | 624M |
| EPS | 0.13 | 0.18 | 0.17 | 0.08 | 0.22 | 0.13 | 0.43 | 0.52 | 0.42 | 0.44 | 0.37 |
| Balance Sheet | |||||||||||
| Total Assets | 1.97B | 2.25B | 2.53B | 3.23B | 3.53B | 3.67B | 4.26B | 4.95B | 5.14B | 5.55B | 5.15B |
| Total Liabilities | 539M | 494M | 516M | 526M | 600M | 766M | 855M | 1.02B | 835M | 811M | 709M |
| Shareholders' Equity | 1.36B | 1.68B | 1.92B | 2.63B | 2.84B | 2.79B | 3.21B | 3.74B | 4.12B | 4.56B | 4.38B |
| Cash & Short-term Investments | 214M | 183M | 146M | 705M | 895M | 1.13B | 1.17B | 1.46B | 1.44B | 250M | 180M |
| Total Debt | 60.0M | 50.0M | 100M | 14.0M | 21.0M | 23.7M | 27.1M | 47.8M | 43.2M | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 258M | 281M | 287M | 296M | 465M | 592M | 699M | 953M | 685M | 863M | - |
| Capital Expenditure | 69.2M | 132M | 214M | 186M | 139M | 131M | 474M | 195M | 117M | 127M | 107M |
| Free Cash Flow | 189M | 149M | 73.8M | 109M | 326M | 461M | 225M | 758M | 568M | 736M | 371M |
| Ratios | |||||||||||
| ROE | 14.5% | 16.6% | 13.7% | 4.7% | 12.7% | 7.4% | 21.9% | 22.7% | 17.1% | 16.1% | 14.2% |
| ROA | 10.0% | 12.3% | 10.4% | 3.9% | 10.2% | 5.6% | 16.5% | 17.1% | 13.8% | 13.3% | 12.1% |
| Net Profit Margin | 23.2% | 25.3% | 18.0% | 7.3% | 21.1% | 9.5% | 30.2% | 29.6% | 27.9% | 27.8% | 28.3% |
| Debt to Equity | 0.04x | 0.03x | 0.05x | 0.01x | 0.01x | 0.01x | 0.01x | 0.01x | 0.01x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Anhui Anke BioTech Group dividends
- Dividend yield
- 3.15%
- Forward dividend
- 0.25 CNY
- Payout ratio
- 56.2%
- Ex-dividend date
- May 29, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 413M | 0.25 | 56.2% |
| 2024 | CNY 416M | 0.25 | 58.8% |
| 2023 | CNY 411M | 0.25 | 48.5% |
| 2022 | CNY 328M | 0.20 | 46.6% |
| 2021 | CNY 273M | 0.17 | 132.2% |
| 2020 | CNY 159M | 0.10 | 44.3% |
| 2019 | CNY 162M | 0.10 | 130.0% |
| 2018 | CNY 111M | 0.07 | 42.3% |
| 2017 | CNY 82.8M | 0.05 | 29.8% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.2:1 on May 14, 2021.
Who owns Anhui Anke BioTech Group
- Insiders 37.59%
- Institutions 4.90%
- Public & others 57.52%
- Shares outstanding 1.67B
- Free float 1.06B
Anhui Anke BioTech Group company profile
- Company name
- Anhui Anke BioTech Group
- Ticker
- 300009.SHE
- ISIN
- CNE100000GY2
- Exchange
- Shenzhen Stock Exchange
- Listed since
- Oct 30, 2009
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 2,505
- Fiscal year end
- December
- Address
- AnkeBio Buildings, Hefei, China, 230088
- Phone
- 86 551 6531 9890
- Website
- ankebio.com
About Anhui Anke BioTech Group
Anhui Anke Biotechnology (Group) Co., Ltd. engages in the biopharmaceutical industry in China and internationally. It offers human growth hormone for injection under the Ansomone name; and recombinant human interferon alpha 2b lyophilized powder, liquid, and prefilled syringe for injection, as well as recombinant human interferon alpha 2b cream, eye drop, and suppository under the Anterferon name. The company provides anti-sperm antibody, semen leukocyte peroxidase staining, one-time semen processing, sperm hypo-osmotic staining, sperm life detection, sperm staining detection, sperm acrosin detection, immunohistochemical, sperm DNA fragmentation staining, leptin, and immunohistochemical diagnostic kits. In addition, it offers adhesive plasters, oral solutions, topical preparations, and ointments; peptide APIs; beauty care products, including anti-aging, masks, essential liquids, and mouthwash; and sybthetic drugs in the form of oral powders, dripping pills, and tablets and capsules. Further, the company provides autosomal, sex chromosome, and other kits; paternity testing, tumor biological immunotherapy technology, and DNA testing services. Additionally, the company offers monoclonal antibody drugs, such as Trastuzumab to treat patients with breast and gastric cancers under the ANTRASTUIN brand; Bevacizumab, an anti-VFDF product; ANKEBIO anti-PD1; and anti-covid19 products. The company was founded in 2000 and is based in Hefei, China.
Anhui Anke BioTech Group management
10- Mr. Lihua Song Ph.D.Chairman of Board of Directors & President · born 1957
- Mr. Chenghao HuFinancial Director & Accounting Supervisor · born 1976
- Mr. Yong Bin WangDirector of Operations & Director · born 1968
- Mr. Jian Ping YaoSenior Vice President · born 1972
- Mr. Hai ShengSenior Vice President · born 1975
- Ms. Hui ZhaoSenior VP & Director · born 1974
- Ms. Chunyan LuVice President · born 1978
- Mr. Kun LiSecretary of the Board & Director · born 1982
- Mr. Xian Yu DuDirector · born 1970
- Ms. Hongyi YaoVice President · born 1972